SGMT

Sagimet Biosciences Inc.

Price Chart

Latest Quote

$6.68

+0.15 (+2.30%)

Current Price

Previous Close	$6.53
Open	$6.55
Day High	$6.86
Day Low	$6.55
Volume	2,627,617

Fetched: 2026-06-20T05:23:18

Stock Information

Shares Outstanding	61.18M
Total Debt	$39K
Cash Equivalents	$104.54M
Net Income	$-43.51M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$412.50M
EPS (TTM)	$-1.34
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$308.00M
Income	$-43.51M
Book/sh	$3.14
Cash/sh	$1.71
Employees	16

Financial Ratios

Quick Ratio	19.74
Current Ratio	20.34
Debt/Eq	0.04

Returns & Margins

ROA	-23.99%
ROE	-36.04%

Ownership

Insider Ownership	3.50%
Institutional Ownership	21.93%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.09
P/B	2.12

Analyst Data

Recommendation	strong_buy
Target Price	$26.20

Technical Indicators

SMA20	$6.81
SMA50	$6.89
SMA200	$6.54
RSI	34.83
ATR	0.3396

Shares Float	59.14M
Short Float	7.92%
Short Ratio	4.95
Rel Volume	4.09

Performance History

Week	+3.89%
Month	+2.14%
Quarter	+38.30%
6 Months	+10.41%
YTD	+11.52%
Year	-2.91%
10 Years	-58.12%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$6.68	3,592,500
2026-06-17	$6.53	794,100
2026-06-16	$6.30	1,246,700
2026-06-15	$6.47	605,500
2026-06-12	$6.48	460,200
2026-06-11	$6.43	763,600
2026-06-10	$6.50	718,800
2026-06-09	$6.52	689,900
2026-06-08	$6.53	621,400
2026-06-05	$6.76	608,200
2026-06-04	$7.06	397,400
2026-06-03	$6.86	662,300
2026-06-02	$6.79	923,900
2026-06-01	$7.19	736,600
2026-05-29	$7.29	628,200
2026-05-28	$7.27	646,000
2026-05-27	$7.22	820,300
2026-05-26	$7.22	909,100
2026-05-22	$7.09	956,500
2026-05-21	$7.00	776,200
2026-05-20	$6.65	732,000
2026-05-19	$6.54	939,500

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

📰 Latest News

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

Zacks • 2026-06-04T13:55:02Z

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade

Zacks • 2026-05-21T13:55:03Z

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Zacks • 2026-05-05T16:00:05Z

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

Zacks • 2026-05-05T13:55:03Z

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

MarketBeat • 2026-05-01T04:07:55Z

Why Sagimet Biosciences Stock Is Soaring Today

Motley Fool • 2026-04-27T16:00:32Z

Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans

InvestorsHub • 2026-04-27T15:13:00Z

Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results

Insider Monkey • 2026-03-25T19:34:32Z

Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.

MarketBeat • 2026-03-01T20:38:51Z

Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference

MarketBeat • 2026-02-15T08:06:16Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$2,000,000	$0
Operating Revenue	$0	$0	$2,000,000	$0
Expenses
Total Expenses	$56,889,000	$54,454,000	$32,740,000	$31,055,000
Net Non Operating Interest Income Expense	$5,851,000	$8,887,000	$2,860,000	$553,000
Operating Expense	$56,889,000	$54,454,000	$32,740,000	$31,055,000
General And Administrative Expense	$17,835,000	$16,010,000	$12,963,000	$6,136,000
Other Income Expense	-	-	$4,000	$3,000
Other Non Operating Income Expenses	-	-	-	$3,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Net Interest Income	$5,851,000	$8,887,000	$2,860,000	$553,000
Interest Income	$5,851,000	$8,887,000	$2,860,000	$553,000
Normalized Income	$-51,038,000	$-45,567,000	$-27,880,000	$-30,502,000
Net Income From Continuing And Discontinued Operation	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Total Operating Income As Reported	$-56,889,000	$-54,454,000	$-30,740,000	$-31,055,000
Net Income Common Stockholders	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Net Income	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Net Income Including Noncontrolling Interests	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Net Income Continuous Operations	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Pretax Income	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Interest Income Non Operating	$5,851,000	$8,887,000	$2,860,000	$553,000
Operating Income	$-56,889,000	$-54,454,000	$-30,740,000	$-31,055,000
Per Share
Diluted EPS	$-1.58	$-1.45	$-2.66	$-1.38
Basic EPS	$-1.58	$-1.45	$-2.66	$-1.38
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-56,889,000	$-54,454,000	$-30,744,000	$-31,058,000
EBITDA (Bullshit earnings)	$-56,889,000	$-54,454,000	$-30,740,000	$-31,055,000
EBIT	$-56,889,000	$-54,454,000	$-30,740,000	$-31,055,000
Diluted Average Shares	$32,345,525	$31,350,725	$10,460,335	$22,174,066
Basic Average Shares	$32,345,525	$31,350,725	$10,460,335	$22,174,066
Diluted NI Availto Com Stockholders	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Research And Development	$39,054,000	$38,444,000	$19,777,000	$24,919,000
Selling General And Administration	$17,835,000	$16,010,000	$12,963,000	$6,136,000
Other Gand A	$17,835,000	$16,010,000	$12,963,000	$6,136,000
Total Unusual Items	-	-	$4,000	$3,000
Total Unusual Items Excluding Goodwill	-	-	$4,000	$3,000
Gain On Sale Of Security	-	-	$4,000	$3,000

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Total Assets	$116,482,000	$160,259,000	$96,719,000	$33,031,000
Total Non Current Assets	$78,000	$7,485,000	$73,000	$239,000
Investmentin Financial Assets	$0	$7,408,000	$0	-
Current Assets	$116,404,000	$152,774,000	$96,646,000	$32,792,000
Other Current Assets	$199,000	$157,000	$74,000	$34,000
Current Deferred Assets	$282,000	$306,000	$323,000	$0
Prepaid Assets	$2,799,000	$1,061,000	$1,352,000	$413,000
Cash Cash Equivalents And Short Term Investments	$113,124,000	$151,250,000	$94,897,000	$32,345,000
Cash And Cash Equivalents	$35,021,000	$75,840,000	$75,139,000	$158,000
Non Current Prepaid Assets	-	-	$0	$27,000
Debt
Total Debt	$78,000	$78,000	$65,000	$211,000
Current Debt And Capital Lease Obligation	$78,000	$78,000	$65,000	$133,000
Long Term Debt And Capital Lease Obligation	-	-	$0	$78,000
Liabilities
Total Liabilities Net Minority Interest	$5,101,000	$4,454,000	$5,654,000	$219,981,000
Total Non Current Liabilities Net Minority Interest	$0	$0	$0	$214,702,000
Current Liabilities	$5,101,000	$4,454,000	$5,654,000	$5,279,000
Other Current Liabilities	$27,000	$5,000	$233,000	$57,000
Payables And Accrued Expenses	$4,996,000	$4,371,000	$5,356,000	$5,089,000
Payables	$1,309,000	$1,425,000	$186,000	$1,125,000
Accounts Payable	$1,309,000	$1,425,000	$186,000	$1,125,000
Derivative Product Liabilities	-	-	$0	$4,000
Equity
Common Stock Equity	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Total Equity Gross Minority Interest	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Stockholders Equity	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Gains Losses Not Affecting Retained Earnings	$120,000	$230,000	$30,000	$-84,000
Other Equity Adjustments	$120,000	$230,000	$30,000	$-84,000
Retained Earnings	$-346,349,000	$-295,311,000	$-249,744,000	$-221,868,000
Preferred Securities Outside Stock Equity	-	-	$0	$214,620,000
Other
Ordinary Shares Number	$32,521,599	$32,195,345	$22,895,892	$22,174,066
Share Issued	$32,521,599	$32,195,345	$22,895,892	$22,174,066
Tangible Book Value	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Invested Capital	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Working Capital	$111,303,000	$148,320,000	$90,992,000	$27,513,000
Capital Lease Obligations	$78,000	$78,000	$65,000	$211,000
Total Capitalization	$111,381,000	$155,805,000	$91,065,000	$-186,950,000
Additional Paid In Capital	$457,607,000	$450,883,000	$340,777,000	$35,001,000
Capital Stock	$3,000	$3,000	$2,000	$1,000
Common Stock	$3,000	$3,000	$2,000	$1,000
Preferred Stock	$0	$0	$0	$0
Current Capital Lease Obligation	$78,000	$78,000	$65,000	$133,000
Current Accrued Expenses	$3,687,000	$2,946,000	$5,170,000	$3,964,000
Investments And Advances	$0	$7,408,000	$0	-
Net PPE	$78,000	$77,000	$73,000	$212,000
Gross PPE	$78,000	$77,000	$73,000	$212,000
Other Properties	$78,000	$77,000	$73,000	$212,000
Other Short Term Investments	$78,103,000	$75,410,000	$19,758,000	$32,187,000
Available For Sale Securities	-	$7,408,000	-	-
Long Term Capital Lease Obligation	-	-	$0	$78,000
Pensionand Other Post Retirement Benefit Plans Current	-	-	$1,105,000	$636,000

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-45,650,000	$-42,435,000	$-23,766,000	$-24,490,000
Operating Activities
Operating Cash Flow	$-45,650,000	$-42,435,000	$-23,766,000	$-24,490,000
Cash Flow From Continuing Operating Activities	$-45,650,000	$-42,435,000	$-23,766,000	$-24,490,000
Operating Gains Losses	-	-	$-4,000	$-3,000
Investing Activities
Investing Cash Flow	$4,556,000	$-61,683,000	$12,580,000	$-32,010,000
Cash Flow From Continuing Investing Activities	$4,556,000	$-61,683,000	$12,580,000	$-32,010,000
Financing Activities
Issuance Of Capital Stock	$0	$105,750,000	$89,679,000	$0
Financing Cash Flow	$275,000	$104,819,000	$86,167,000	$-73,000
Cash Flow From Continuing Financing Activities	$275,000	$104,819,000	$86,167,000	$-73,000
Net Common Stock Issuance	$0	$105,750,000	$89,679,000	$0
Common Stock Issuance	$0	$105,750,000	$89,679,000	$0
Net Other Financing Charges	-	$-1,045,000	$-3,518,000	$-85,000
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
End Cash Position	$35,021,000	$75,840,000	$75,139,000	$158,000
Beginning Cash Position	$75,840,000	$75,139,000	$158,000	$56,731,000
Changes In Cash	$-40,819,000	$701,000	$74,981,000	$-56,573,000
Proceeds From Stock Option Exercised	$275,000	$114,000	$6,000	$12,000
Net Investment Purchase And Sale	$4,556,000	$-61,683,000	$12,580,000	$-32,010,000
Sale Of Investment	$111,420,000	$46,404,000	$32,200,000	$9,436,000
Purchase Of Investment	$-106,864,000	$-108,087,000	$-19,620,000	$-41,446,000
Change In Working Capital	$-1,053,000	$-1,048,000	$-978,000	$4,214,000
Change In Other Current Liabilities	$-152,000	$-136,000	$-146,000	$-137,000
Change In Payables And Accrued Expense	$929,000	$-907,000	$120,000	$2,915,000
Change In Prepaid Assets	$-1,830,000	$-5,000	$-952,000	$1,436,000
Other Non Cash Items	$151,000	$145,000	$139,000	$130,000
Stock Based Compensation	$6,449,000	$5,288,000	$4,990,000	$1,880,000
Asset Impairment Charge	$230,000	$0	-	-
Amortization Of Securities	$-389,000	$-1,253,000	$-37,000	$-212,000
Net Income From Continuing Operations	$-51,038,000	$-45,567,000	$-27,876,000	$-30,499,000
Gain Loss On Investment Securities	-	-	$-4,000	$-3,000
Unrealized Gain Loss On Investment Securities	-	-	-	$0

Fetched: 2026-06-15